{"id":"W3191554850","doi":"10.1177/17588359211036544","title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Gemcitabine; Clinical endpoint; Oncology; Chemotherapy; Internal medicine; Tumor microenvironment; Cancer; Immunotherapy; Clinical trial; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002436336,0.00212142,0.003065175,0.0005486424,0.0004301202,0.001580283,0.001383435,0.002147431,0.006543014],"category_scores_gemma":[0.001805133,0.001021407,0.002011464,0.0004242197,0.001488774,0.001582963,0.0006365224,0.003547482,0.001477927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001082897,"about_ca_system_score_gemma":0.001466801,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007665218,"about_ca_topic_score_gemma":0.00173236,"domain_scores_codex":[0.9991652,0.0004699127,0.00004430403,0.0001499867,0.00004751039,0.0001230854],"domain_scores_gemma":[0.9988291,0.0002109523,0.0002427655,0.0001020398,0.00006821458,0.0005469184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.970453,0.01062504,0.0009362287,0.0004371131,0.000679648,0.00003670267,0.00004745902,0.0003943845,0.003796405,0.0001356135,0.0009852177,0.01147327],"study_design_scores_gemma":[0.9011625,0.09551803,0.001449541,0.00002084545,0.0003083042,0.00004302763,0.00001929666,0.0004103572,0.0003199599,0.00008730951,0.0006451154,0.00001573598],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850925,0.003587869,0.0005412904,0.001098055,0.0007221345,0.004654336,0.001152459,0.0001829793,0.002968434],"genre_scores_gemma":[0.9809124,0.001960466,0.001889592,0.002264721,0.0006242116,0.005762038,0.002669657,0.00004236648,0.003874636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006543014,"threshold_uncertainty_score":0.02188855,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01165188480779092,"score_gpt":0.3378004446659155,"score_spread":0.3261485598581245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}